Dorzolamide
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Dorzolamide
- Pharmacist Assessment Report
- Dorzolamide: Carbonic anhydrase inhibitor → Hypotrichosis simplex of the scalp
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Dorzolamide: Carbonic anhydrase inhibitor → Hypotrichosis simplex of the scalp
One-Sentence Summary
Dorzolamide is a topical carbonic anhydrase inhibitor that is marketed in Canada. The TxGNN model predicts it may be relevant to hypotrichosis simplex of the scalp, with a score of 0.9995. There are currently no clinical trials and no publications on this disease in the data compiled for this report, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 11 of 11) |
| Number of DINs | 11 (marketed: 11) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Dorzolamide acts on carbonic anhydrase enzymes. The data compiled for this report list human carbonic anhydrase 1, 7, 12 and 14 as its pharmacological targets. Detailed mechanism-of-action text is not available.
No clear mechanistic link connects carbonic anhydrase inhibition to hair follicle biology in hereditary hypotrichosis. The high score therefore looks like a statistical pattern in the model rather than a pharmacological rationale. Nothing in the compiled data (trials, literature or a pathway argument) supports it.
The prediction should be treated as a hypothesis for the model’s developers to examine, not as a lead with a demonstrated biological basis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Dorzolamide is marketed in Canada, and every licence on record is valid. Dosage form and indication text are not recorded in the local data. The licence list is generated by the site program.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has the lowest evidence level (L5). No trials or publications address this disease, and no plausible mechanism links carbonic anhydrase inhibition to hair follicle disorders. The score alone is not enough to justify further investment.
To proceed, the following is needed:
- A mechanistic hypothesis that explains how carbonic anhydrase inhibition could affect hair follicle biology
- Preclinical or case-level evidence that directly addresses this disease
- Package insert warnings and contraindications from Health Canada, to support safety screening
- Confirmation that a topical route and formulation would be suitable for scalp use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.